Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. [electronic resource]
Producer: 20190624Description: 421-428.e1 p. digitalISSN:- 1938-0682
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antineoplastic Agents, Immunological -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Transitional Cell -- drug therapy
- Deoxycytidine -- analogs & derivatives
- Docetaxel -- pharmacology
- Drug Resistance, Neoplasm
- Feasibility Studies
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neutropenia -- chemically induced
- Platinum Compounds -- pharmacology
- Progression-Free Survival
- Response Evaluation Criteria in Solid Tumors
- Urologic Neoplasms -- drug therapy
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.